Johnson & Johnson COVID-19 vaccine generates immune response in trial

Johnson & Johnson COVID-19 vaccine generates immune response in trial


Johnson
&
Johnson’s
coronavirus
vaccine

generated
a
lasting
immune
response
to
the
deadly
bug
in
an
early-stage
clinical
trial,
the
pharmaceutical
giant
said.

More
than
90
percent
of
the
study’s
805
participants
had
neutralizing
antibodies
offering
protection
against
COVID-19
29
days
after
receiving
a
single
dose
of
the
vaccine,

the
New
Jersey-based
drugmaker
said
Wednesday
.

The
antibodies
stuck
around
for
at
least
71
days
among
the
participants
ranging
in
age
from
18
to
55
years
old,
according
to
interim
results

published
in
the
New
England
Journal
of
Medicine
.
J&J
said
it
will
have
data
later
this
month
on
the
durability
of
immunity
in
people
older
than
65.

The
early
data
showed
signs
of
promise
for
Johnson
&
Johnson’s
one-shot
vaccine
even
as
the
company

reportedly
hit
a
snag

in
producing
the
inoculations.

J&J
said
it
expects
to
announce
results
from
its
key
late-stage
vaccine
trial
late
this
month.
It
will
then
ask
the
Food
and
Drug
Administration
to
clear
the
shot
for
emergency
use
if
the
data
show
it
is
safe
and
effective.

Early
safety
data
showed
that
people
who
had
reactions
to
the
vaccine
generally
got
better
within
24
hours,
the
company
said.
The
most
common
side
effects
were
headaches,
muscle
pain,
fatigue
and
pain
at
the
injection
site.

The
Johnson
&
Johnson
vaccine
is

different
from
the
Pfizer
and
Moderna
shots

being
distributed
across
the
country.

The
latter
companies’
vaccines
require
two
doses
and
use
genetic
material
called
messenger
RNA
to
direct
the
body
to
create
a
tiny
amount
of
coronavirus
spike
proteins,
triggering
an
immune
response.
Johnson
&
Johnson’s
requires
just
one
dose
and
delivers
the
spike
proteins
through
a
disabled
common
cold
virus
that
can’t
infect
the
recipient.

J&J
also
studied
a
two-dose
regimen
of
its
vaccine
and
found
that
the
second
dose,
given
56
days
apart,
“triggered
more
than
a
two-fold
increase
in
antibodies

against
COVID-19
,”
the
company
said.

Johnson
&
Johnson
shares
jumped
1.7
percent
in
premarket
trading
Thursday
to
$160.68
as
of
7:42
a.m.

Category Latest Posts